[go: up one dir, main page]

TWI590837B - 一種用於治療心臟病之吸入式醫藥組成物及其備製方法 - Google Patents

一種用於治療心臟病之吸入式醫藥組成物及其備製方法 Download PDF

Info

Publication number
TWI590837B
TWI590837B TW103110985A TW103110985A TWI590837B TW I590837 B TWI590837 B TW I590837B TW 103110985 A TW103110985 A TW 103110985A TW 103110985 A TW103110985 A TW 103110985A TW I590837 B TWI590837 B TW I590837B
Authority
TW
Taiwan
Prior art keywords
gas
pharmaceutical composition
inhaled pharmaceutical
heart disease
hydrogen
Prior art date
Application number
TW103110985A
Other languages
English (en)
Other versions
TW201536359A (zh
Inventor
林信湧
Original Assignee
林信湧
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 林信湧 filed Critical 林信湧
Priority to TW103110985A priority Critical patent/TWI590837B/zh
Priority to CN201410337827.1A priority patent/CN104940223A/zh
Priority to US14/664,491 priority patent/US9375396B2/en
Priority to DE102015104360.2A priority patent/DE102015104360A1/de
Priority to JP2015060834A priority patent/JP2015183006A/ja
Priority to KR1020150041704A priority patent/KR20150111328A/ko
Publication of TW201536359A publication Critical patent/TW201536359A/zh
Application granted granted Critical
Publication of TWI590837B publication Critical patent/TWI590837B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
    • A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
    • A61M11/044—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical with electrodes immersed in the liquid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
    • A61M11/045—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters using another liquid as heat exchanger, e.g. bain-marie
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/36—General characteristics of the apparatus related to heating or cooling
    • A61M2205/3693—General characteristics of the apparatus related to heating or cooling by mechanical waves, e.g. ultrasonic

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Description

一種用於治療心臟病之吸入式醫藥組成物及其備製方法
本發明係有關於一種吸入式醫藥組成物及其備製方法，特別是有關於一種用於治療心臟病之吸入式醫藥組成物及其備製方法。
目前，隨著人們生活水準的不斷提高，生活型態改變及飲食習慣逐漸西化，以致心臟病(Heart Disease)病患人數大幅增加，且高居國內十大死因之一，同時發病年齡層也有明顯下降的趨勢，所以心臟病已經嚴重地威脅到人類健康。
心臟病是心臟疾病的總稱，其影響著心臟的結構和功能，可分為先天性心臟病、風濕性心臟病、高血壓性心臟病和冠狀動脈心臟病，其中心臟病致病的主因是冠狀動脈出現狹窄、硬化或阻塞以致心臟的血液供應不足而引起心臟缺氧，即所謂的冠狀動脈心臟病(Coronary Artery Disease,CAD)，其包含有冠狀動脈硬化症、冠狀動脈粥狀硬化、冠心病、缺血性心臟病、心絞痛、狹心症、心肌梗塞。
其中於先前技術中，冠狀動脈疾病的藥物治療法包括：抗血小板凝擬集藥物，如乙醯水楊酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)；乙受型阻斷劑，如普萘洛爾(Propranolol)、阿替洛爾 (Atenolol)、納得洛(Nadolol)、卡維地洛(Carvedilol)；鈣離子通道阻斷劑，如硝苯吡啶(Nifedipine)、迪耳替阿簡(Diltiazem)、維拉帕米(Verapamil)；硝酸鹽類，如硝酸異山梨酯(Isosorbide Dinitrate)、尼可拉定(Nicorandil)；以及硝酸甘油(Nitroglycerin,NTG)。然而，上述這些藥物通常都存在有一些副作用，例如，服藥後會出現如頭痛或心跳加快等不良反應，甚至有患者在服用硝酸甘油後會出現昏迷的現象，使得這些藥物不適合長期使用。
如上所述，因此目前缺乏一種能兼具治療效果且降低對患者產生副作用之心臟病之藥劑。
有鑒於此，本發明提供一種用於治療心臟病之吸入式醫藥組成物，其包含一第一氣體及一霧化藥液。第一氣體包含一氫氣，氫氣佔吸入式醫藥組成物之氣體體積濃度介於2%~96%之間。霧化藥液包含選自於乙醯水楊酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛爾(Propranolol)、阿替洛爾(Atenolol)、納得洛(Nadolol)、卡維地洛(Carvedilol)、硝苯吡啶(Nifedipine)、迪耳替阿簡(Diltiazem)、維拉帕米(Verapamil)、硝酸異山梨酯(Isosorbide Dinitrate)、尼可拉定(Nicorandil)以及硝酸甘油(Nitroglycerin)所組成族群中之一或其組合。
根據本發明之一實施例提供一種用於治療心臟病之吸入式醫藥組成物，第一氣體係藉由電解水所產生之一氫氧混合氣體，其氫氣與氧氣之體積比為2：1。於一實施例中，氫氣佔吸入式醫藥組成物之氣體體積濃度介於2%~66.66%之間。此外，本發明吸入式醫藥組成物另包含一第二氣體，用以降低吸入式醫藥組成物中氫氣之氣體體積濃度，其中第二氣 體係為選自於由空氣、水蒸汽、鈍氣、氧氣及其組合所組成族群中的一種氣體。於另一實施例中，氫氣佔吸入式醫藥組成物之氣體體積濃度介於4.7%~66.66%之間。
根據本發明之另一實施例提供一種用於治療心臟病之吸入式醫藥組成物，氫氣佔吸入式醫藥組成物之氣體體積濃度介於60%~66.66%之間。此外，於另一實施例提供一種用於治療心臟病之吸入式醫藥組成物，氫氣佔吸入式醫藥組成物之氣體體積濃度大於66.66%。
此外，本發明另提供一種用於治療心臟病之吸入式醫藥組成物之製備方法，包含下列步驟：(S1)備製一第一氣體，第一氣體包含一氫氣；(S2)霧化一藥液以產生一霧化藥液，藥液包含選自於乙醯水楊酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛爾(Propranolol)、阿替洛爾(Atenolol)、納得洛(Nadolol)、卡維地洛(Carvedilol)、硝苯吡啶(Nifedipine)、迪耳替阿簡(Diltiazem)、維拉帕米(Verapamil)、硝酸異山梨酯(Isosorbide Dinitrate)、尼可拉定(Nicorandil)以及硝酸甘油(Nitroglycerin)所組成族群中之一或其組合；以及(S3)混合第一氣體以及霧化藥液以產生該吸入式醫藥組成物，其中氫氣佔吸入式醫藥組成物之氣體體積濃度介於2%~96%之間。
根據本發明之一實施例提供一種用於治療心臟病之吸入式醫藥組成物之製備方法，本發明方法之步驟(S1)係為電解水以產生第一氣體，第一氣體含一氫氧混合氣體，其氫氣與氧氣之體積比為2：1。
根據本發明之另一實施例提供一種用於治療心臟病之吸入 式醫藥組成物之製備方法，本發明方法之步驟包含：(S21)備製一第一氣體，第一氣體包含一氫氣；(S22)霧化一藥液以產生一霧化藥液，藥液包含選自於乙醯水楊酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛爾(Propranolol)、阿替洛爾(Atenolol)、納得洛(Nadolol)、卡維地洛(Carvedilol)、硝苯吡啶(Nifedipine)、迪耳替阿簡(Diltiazem)、維拉帕米(Verapamil)、硝酸異山梨酯(Isosorbide Dinitrate)、尼可拉定(Nicorandil)以及硝酸甘油(Nitroglycerin)所組成族群中之一或其組合；(S23)準備一第二氣體；以及(S24)混合第一氣體、第二氣體以及霧化藥液以產生吸入式醫藥組成物，其中第二氣體用以降低吸入式醫藥組成物中該氫氣之氣體體積濃度。於此實施例中，本發明用於治療心臟病之吸入式醫藥組成物中氫氣佔吸入式醫藥組成物之氣體體積濃度，可因第二氣體加入而降低吸入式醫藥組成物中該氫氣之氣體體積濃度。
此外，根據本發明之另一實施例提供一種用於治療心臟病之吸入式醫藥組成物之製備方法，其中氫氣佔吸入式醫藥組成物之氣體體積濃度介於60%~66.66%之間。於另一實施例提供一種用於治療心臟病之吸入式醫藥組成物之製備方法，其中氫氣佔吸入式醫藥組成物之氣體體積濃度大於66.66%。
相較於習知技術，本發明提供一種用於治療心臟病之吸入式醫藥組成物及其製備方法，本發明吸入式醫藥組成物除了可以提供患者直接吸入之服用便利性外，並可以藉由氫氣以去除患者體內之惡性自由基， 並藉由霧化藥液以增加患者之藥物吸收療效。
S1~S3、S21~S24‧‧‧流程步驟
100‧‧‧電解裝置
102‧‧‧電解槽
104‧‧‧電解水
106A、106B‧‧‧電極
108‧‧‧第一氣體
110‧‧‧第一氣體管路
200‧‧‧氣體混合系統
210‧‧‧霧化/揮發氣體混合槽
212‧‧‧霧化藥液
214‧‧‧吸入式醫藥組成物
216‧‧‧震盪器
220‧‧‧藥液
第一圖係繪示本發明之用於治療心臟病之吸入式醫藥組成物之製備方法於一具體實施例之方法流程圖。
第二圖係繪示本發明之用於治療心臟病之吸入式醫藥組成物之製備方法於另一具體實施例之方法流程圖。
第三圖係繪示本發明之用於治療心臟病之吸入式醫藥組成物之製備方法中步驟(S1)於一具體實施例之電解裝置示意圖。
第四圖係繪示本發明之用於治療心臟病之吸入式醫藥組成物之製備方法中步驟(S2)及(S3)於一具體實施例之氣體混合系統之示意圖。
為了讓本發明的優點，精神與特徵可以更容易且明確地了解，後續將以實施例並參照所附圖式進行詳述與討論。值得注意的是，這些實施例僅為本發明代表性的實施例，其中所舉例的特定方法、裝置、條件、材質等並非用以限定本發明或對應的實施例。
本發明提出一種用於治療心臟病之吸入式醫藥組成物，其包含一第一氣體及一霧化藥液。第一氣體包含一氫氣，氫氣佔吸入式醫藥組成物之氣體體積濃度介於2%~96%之間。霧化藥液包含選自於乙醯水楊酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛爾(Propranolol)、阿替洛爾(Atenolol)、納得洛(Nadolol)、卡維地洛(Carvedilol)、硝苯吡啶(Nifedipine)、迪耳替阿簡(Diltiazem)、維拉帕米(Verapamil)、硝酸異山梨酯(Isosorbide Dinitrate)、尼可拉定(Nicorandil)以及硝酸甘油(Nitroglycerin)所組 成族群中之一或其組合。
於本發明之實施例中，第一氣體更包含一氧氣，而第一氣體係藉由電解水所產生之一氫氧混合氣體，其氫氣與氧氣之體積比為2：1。而霧化藥液則係藉由針對一藥液進行霧化或揮發所產生，其中藥液包含選自於乙醯水楊酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛爾(Propranolol)、阿替洛爾(Atenolol)、納得洛(Nadolol)、卡維地洛(Carvedilol)、硝苯吡啶(Nifedipine)、迪耳替阿簡(Diltiazem)、維拉帕米(Verapamil)、硝酸異山梨酯(Isosorbide Dinitrate)、尼可拉定(Nicorandil)以及硝酸甘油(Nitroglycerin)所組成族群中之一或其組合，且上述藥物應用於心臟病治療上已為本領域的技術人員所熟知，故在此不多加贅述。於本實施例中，氫氣佔吸入式醫藥組成物之氣體體積濃度介於2%~66.66%之間。
本發明吸入式醫藥組成物另包含一第二氣體，第二氣體用以降低吸入式醫藥組成物中氫氣之氣體體積濃度，其中第二氣體係為選自於由空氣、水蒸汽、鈍氣、氧氣及其組合所組成族群中的一種氣體。於本實施例中，氫氣佔吸入式醫藥組成物之氣體體積濃度可介於4.7%~66.66%之間，惟不以此範圍為限。
於另一具體實施例中，本發明吸入式醫藥組成物可以藉由混合第一氣體以及霧化一體積為40c.c.之藥液所產生之霧化藥液所製備，而氫氣佔吸入式醫藥組成物之氣體體積濃度介於60%~66.66%之間。於另一實施例中，也可以用氫氣瓶提供所需氫氣，並與霧化藥液進行混合，此時氫氣佔吸入式醫藥組成物之氣體體積濃度將可能會高於66.66%，例如67%~96%之間。於另一實施例中，也可直接蒐集電解水中所產生之氫氣(而非氫氧混 合氣)直接與霧化藥液進行混合，此時氫氣佔吸入式醫藥組成物之氣體體積濃度將也會高於66.66%。
請參閱第一圖，係繪示本發明之用於治療心臟病之吸入式醫藥組成物之製備方法於一具體實施例之方法流程圖。如圖所示，本發明吸入式醫藥組成物之製備方法包含下列步驟：(S1)備製一第一氣體，第一氣體包含有一氫氣；(S2)霧化一藥液以產生一霧化藥液，藥液包含有選自於乙醯水楊酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛爾(Propranolol)、阿替洛爾(Atenolol)、納得洛(Nadolol)、卡維地洛(Carvedilol)、硝苯吡啶(Nifedipine)、迪耳替阿簡(Diltiazem)、維拉帕米(Verapamil)、硝酸異山梨酯(Isosorbide Dinitrate)、尼可拉定(Nicorandil)以及硝酸甘油(Nitroglycerin)所組成族群中之一或其組合；以及(S3)混合第一氣體以及霧化藥液以產生吸入式醫藥組成物，其中氫氣佔吸入式醫藥組成物之氣體體積濃度介於2%~96%之間。
根據本發明之一實施例提供一種用於治療心臟病之吸入式醫藥組成物之製備方法，本發明方法之步驟(S1)係為電解水以產生第一氣體，第一氣體含一氫氧混合氣體，其氫氣與氧氣之體積比為2：1。於一實施例中，氫氣佔吸入式醫藥組成物之氣體體積濃度介於2%~66.66%之間，惟不以此範圍為限。
請參閱第二圖，係繪示本發明之用於治療心臟病之吸入式醫藥組成物之製備方法於另一具體實施例之方法流程圖。如圖所示，本發明吸入式醫藥組成物之另一製備方法，包含下列步驟： (S21)備製一第一氣體，第一氣體包含有一氫氣；(S22)霧化一藥液以產生一霧化藥液，藥液包含有選自於乙醯水楊酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛爾(Propranolol)、阿替洛爾(Atenolol)、納得洛(Nadolol)、卡維地洛(Carvedilol)、硝苯吡啶(Nifedipine)、迪耳替阿簡(Diltiazem)、維拉帕米(Verapamil)、硝酸異山梨酯(Isosorbide Dinitrate)、尼可拉定(Nicorandil)以及硝酸甘油(Nitroglycerin)所組成族群中之一或其組合；以及(S23)準備一第二氣體；以及(S24)混合第一氣體、第二氣體以及霧化藥液以產生吸入式醫藥組成物。
根據本發明之一實施例提供一種用於治療心臟病之吸入式醫藥組成物之製備方法，本發明方法之步驟(S21)係為電解水以產生第一氣體，第一氣體含一氫氧混合氣體，其氫氣與氧氣之體積比為2：1。此外，本發明用於治療心臟病之吸入式醫藥組成物中氫氣佔吸入式醫藥組成物之氣體體積濃度，可因第二氣體加入而降低吸入式醫藥組成物中該氫氣之氣體體積濃度，於本實施例中，氫氣佔吸入式醫藥組成物之氣體體積濃度可介於4.7%~66.66%之間，惟不以此範圍為限。
當然，於另一實施例中，也可以用氫氣瓶提供所需氫氣，並與霧化藥液進行混合，此時氫氣佔吸入式醫藥組成物之氣體體積濃度將可能會高於66.66%，例如67%~96%之間。但因吸入氣體中氫氣體積濃度太高(如高於96%)可能使氧氣體積濃度太低而對人體產生缺氧之不良影響，因此此時需注意控制氫氣體積濃度不要高於96%，如介於67%~90%之間。於另 一實施例中，也可直接蒐集電解水中所產生之氫氣(而非氫氧混合氣)直接與霧化藥液進行混合，此時氫氣佔吸入式醫藥組成物之氣體體積濃度將也會高於66.66%。
請參閱第三圖，係繪示本發明之用於治療心臟病之吸入式醫藥組成物之製備方法中步驟(S1)於一具體實施例之電解裝置示意圖。於本實施例中，本發明能夠藉由電解水以產生含有氫氧混合氣體之第一氣體，其中電解裝置100包含一電解槽102、一電解水104、電極106A、106B以及一電源。
首先，電解槽102用以容納電解水104，其中電解水104主要成份為純水，惟不以此為限，於實際應用時，電解水能夠視需要以添加少量的電解質，如氫氧化鈉、碳酸鈣、氯化鈉等。再者，電解槽102中包含電極106A、106B，電極106A、106B分別為一陰極電極及一陽極電極，並耦接至一電源(未繪示於圖中)，藉以提供電解水所需之電能。於一具體實施例中，電極106A、106B能夠是固定的極性，如電極106A為陰極，電極106B為陽極，惟電極的極性不以固定為限。於另一具體實施例中，電極106A、106B能夠是交替變換的極性，如在某一時間點，電極106A為陰極，電極106B為陽極；經過一預定時間後，在另一時間點，電極106A切換為陽極，電極106B切換為陰極，其後依此類推。
接著，電解槽102中的電解水104經過電極106A、106B通電後會開始電解，而在陰極(負極)產生氫氣，陽極(正極)產生氧氣，且釋出於電解槽102的上部，以形成一第一氣體108，其中第一氣體108由電解槽102的第一氣體管路110輸出，以作為後續的使用，惟不以此為限。於另一個實 施例中，本發明亦能夠將陰極產生之氫氣與陽極產生之氧氣，個別以一氣體導管導引出電解槽102，之後再進行混合而產生第一氣體108。
由於電解水104經過電解後所產生的氫氣及氧氣之體積比約為2：1。於一具體實施例中，本發明能夠再添加第二氣體112，藉以降低吸入式醫藥組成物中該氫氣之氣體體積濃度，例如氫氣佔吸入式醫藥組成物之氣體體積濃度可以控制介於4.7%~66.66%之間，其中第二氣體係為選自於由空氣、水蒸汽、鈍氣、氧氣及其組合所組成族群中的一種氣體。
請參閱第四圖，係繪示本發明之用於治療心臟病之吸入式醫藥組成物之製備方法中步驟(S2)及(S3)於一具體實施例之氣體混合系統之示意圖。本發明吸入式醫藥組成物之製備方法中步驟(S2)及(S3)可以藉由氣體混合系統200，藉以霧化藥液220並混合第一氣體108進而產生吸入式醫藥組成物214。
氣體混合系統200包含一霧化/揮發氣體混合槽210，霧化/揮發氣體混合槽210藉由第一氣體管路110與電解裝置100(如第三圖所示)耦接，以接收第一氣體108，並與霧化藥液212混合，以形成吸入式醫藥組成物214。霧化/揮發氣體混合槽210更包括一震盪器216(例如超音波震盪器)，適於對霧化/揮發氣體混合槽210中藥液220進行霧化，以產生霧化藥液212。藥液220可以為乙醯水楊酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛爾(Propranolol)、阿替洛爾(Atenolol)、納得洛(Nadolol)、卡維地洛(Carvedilol)、硝苯吡啶(Nifedipine)、迪耳替阿簡(Diltiazem)、維拉帕米(Verapamil)、硝酸異山梨酯(Isosorbide Dinitrate)、尼可拉定(Nicorandil)以及硝酸甘油(Nitroglycerin)所組成族群中之一或其組合，且上述藥物應用於心 臟病治療上已為本領域的技術人員所熟知，故在此不多加贅述。
於另一具體實施例中，霧化/揮發氣體混合槽210中可容納之藥液約40~100c.c之範圍，預估以60分鐘內霧化完畢，故霧化藥液本身產氣量約0.67cc/min~1.67cc/min之間，而電解槽102控制每分鐘產氣量約2,000cc/min~3,000cc/min之間，其中如電解槽產氣之結果僅僅是氫氧混合氣(氫氣及氧氣之體積比約為2：1)，則氫氣佔吸入式醫藥組成物之氣體體積濃度介於66.61%~66.65%之間。但有時因電解槽電解之熱能，會蒸發電解水而使電解槽產氣之結果除氫氧混合氣外，還可能含有少量些許之水蒸氣，因此氫氣佔吸入式醫藥組成物之氣體體積濃度會低於66.61%，例如介於60%~66.61%之間，當然上述之少量些許水蒸氣可以藉由降溫而減少。本發明吸入式醫藥組成物之備製方法可以藉由混合氫氧混合氣以及霧化藥液所製備，一般而言氫氣佔吸入式醫藥組成物之氣體體積濃度介於60%~66.66%之間。
由上述實施例可知，本發明吸入式醫藥組成物包含氫氣與霧化藥液，以提供患者(未繪示)吸入。人體因各種原因，(比如疾病、飲食、所處環境或生活習慣)引生的惡性自由基，亦稱有害自由基，可以與吸入的氫氣還原成部份的水，而排出體外。間接減少人體自由基的數量，達到酸性體質還原至健康的鹼性體質，可以抗氧化進而也達到消除慢性疾病效果。另外，液態藥液經過霧化後形成1~5微米的藥水粒子，經由吸入的方式，而透過鼻黏膜或肺泡直接吸收，可以更有利於人體吸收，也就是說較少霧化藥液劑量即可達成原先一般口服或注射所需要藥劑量之治療效果，也因為使用少量霧化藥液劑量，也間接降低藥劑對人體產生之副作用。當然藥液也可以是口服藥溶於水後之混合液。因此，本發明藉由具有氫氧與霧化 藥液之吸入式醫藥組成物，供人體吸入後可以達成更好之治療或醫療效果。
相較於習知技術，本發明提供一種用於治療心臟病之吸入式醫藥組成物及其製備方法，本發明吸入式醫藥組成物除了可以藉由氫氣以去除患者體內之惡性自由基，並藉由霧化藥液以增加患者之藥物吸收療效，透過較少霧化藥液劑量即可達成原先一般口服或注射所需要藥劑量之治療效果，因而能使用少量霧化藥液劑量，間接地降低藥劑對人體產生之副作用。
藉由以上較佳具體實施例之詳述，係希望能更加清楚描述本發明之特徵與精神，而並非以上述所揭露的較佳具體實施例來對本發明之範疇加以限制。相反地，其目的是希望能涵蓋各種改變及具相等性的安排於本發明所欲申請之專利範圍的範疇內。因此，本發明所申請之專利範圍的範疇應根據上述的說明作最寬廣的解釋，以致使其涵蓋所有可能的改變以及具相等性的安排。
S1~S3‧‧‧流程步驟

Claims (15)

  1. 一種用於治療心臟病之吸入式醫藥組成物，其包含一第一氣體及一霧化藥液，其中該第一氣體包含一氫氣及一氧氣，該氫氣佔該吸入式醫藥組成物之氣體體積濃度介於4.7%~96%之間，該霧化藥液包含選自於乙醯水楊酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛爾(Propranolol)、阿替洛爾(Atenolol)、納得洛(Nadolol)、卡維地洛(Carvedilol)、硝苯吡啶(Nifedipine)、迪耳替阿簡(Diltiazem)、維拉帕米(Verapamil)、硝酸異山梨酯(Isosorbide Dinitrate)、尼可拉定(Nicorandil)以及硝酸甘油(Nitroglycerin)所組成族群中之一或其組合。
  2. 如申請專利範圍第1項所述之用於治療心臟病之吸入式醫藥組成物，其中該第一氣體係藉由電解水所產生之一氫氧混合氣體，其氫氣與氧氣之體積比為2：1。
  3. 如申請專利範圍第1項所述之用於治療心臟病之吸入式醫藥組成物，另包含一第二氣體，用以降低該吸入式醫藥組成物中該氫氣之氣體體積濃度，其中該第二氣體係為選自於由空氣、水蒸汽、鈍氣及其組合所組成族群中的一種氣體。
  4. 如申請專利範圍第1項所述之用於治療心臟病之吸入式醫藥組成物，其中該氫氣佔該吸入式醫藥組成物之氣體體積濃度介於4.7%~66.66%之間。
  5. 如申請專利範圍第1項所述之用於治療心臟病之吸入式醫藥組成物，其中該氫氣佔該吸入式醫藥組成物之氣體體積濃度介於60%~66.66%之間。
  6. 如申請專利範圍第1項所述之用於治療心臟病之吸入式醫藥組成物，該氫氣佔該吸入式醫藥組成物之氣體體積濃度大於66.66%。
  7. 如申請專利範圍第1項所述之用於治療心臟病之吸入式醫藥組成物，其中該霧化藥液係藉由針對一藥液進行霧化或揮發所產生。
  8. 一種用於治療心臟病之吸入式醫藥組成物之製備方法，包含下列步驟：(S1)備製一第一氣體，該第一氣體包含一氫氣及一氧氣；(S2)霧化一藥液以產生一霧化藥液，該藥液包含選自於乙醯水楊酸(Acetylsalicylic Acid)、氯吡格雷(Clopidogrel)、普萘洛爾(Propranolol)、阿替洛爾(Atenolol)、納得洛(Nadolol)、卡維地洛(Carvedilol)、硝苯吡啶(Nifedipine)、迪耳替阿簡(Diltiazem)、維拉帕米(Verapamil)、硝酸異山梨酯(Isosorbide Dinitrate)、尼可拉定(Nicorandil)以及硝酸甘油(Nitroglycerin)所組成族群中之一或其組合；以及(S3)混合該第一氣體以及該霧化藥液以產生該吸入式醫藥組成物，其中該氫氣佔該吸入式醫藥組成物之氣體體積濃度介於4.7%~96%之間。
  9. 如申請專利範圍第8項所述之用於治療心臟病之吸入式醫藥組成物之製備方法，於步驟(S3)中更混合一第二氣體。
  10. 如申請專利範圍第8項所述之用於治療心臟病之吸入式醫藥組成物之製備方法，其中步驟(S1)係為電解水以產生該第一氣體，該第一氣體含一氫氧混合氣體，其氫氣與氧氣之體積比為2：1。
  11. 如申請專利範圍第9項所述之用於治療心臟病之吸入式醫藥組成物之製備方法，其中該第二氣體用以降低該吸入式醫藥組成物中該氫氣之氣體體積濃度。
  12. 如申請專利範圍第9項所述之用於治療心臟病之吸入式醫藥組成物之製備方法，其中該第二氣體係為選自於由空氣、水蒸汽、鈍氣及其組合所組成族群中的一種氣體。
  13. 如申請專利範圍第8項所述之用於治療心臟病之吸入式醫藥組成物之製備方法，其中該氫氣佔該吸入式醫藥組成物之氣體體積濃度介於 4.7%~66.66%之間。
  14. 如申請專利範圍第8項所述之用於治療心臟病之吸入式醫藥組成物之製備方法，其中該氫氣佔該吸入式醫藥組成物之氣體體積濃度介於60%~66.66%之間。
  15. 如申請專利範圍第8項所述之用於治療心臟病之吸入式醫藥組成物之製備方法，其中該氫氣佔該吸入式醫藥組成物之氣體體積濃度大於66.66%。
TW103110985A 2014-03-25 2014-03-25 一種用於治療心臟病之吸入式醫藥組成物及其備製方法 TWI590837B (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
TW103110985A TWI590837B (zh) 2014-03-25 2014-03-25 一種用於治療心臟病之吸入式醫藥組成物及其備製方法
CN201410337827.1A CN104940223A (zh) 2014-03-25 2014-07-16 一种用于治疗心脏病的吸入式药物组合物及其制备方法
US14/664,491 US9375396B2 (en) 2014-03-25 2015-03-20 Inhalation-type pharmaceutical composition for the treatment of heart disease and preparation method thereof
DE102015104360.2A DE102015104360A1 (de) 2014-03-25 2015-03-24 Pharmazeutische zusammensetzung vom inhalationstyp für die behandlung einer herzkrankheit und zubereitungsverfahren dafür
JP2015060834A JP2015183006A (ja) 2014-03-25 2015-03-24 心疾患を治療するための吸入式医薬組成物及びその調製法
KR1020150041704A KR20150111328A (ko) 2014-03-25 2015-03-25 흡입형 심장병 치료용 약제 조성물 및 이의 제조 방법

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW103110985A TWI590837B (zh) 2014-03-25 2014-03-25 一種用於治療心臟病之吸入式醫藥組成物及其備製方法

Publications (2)

Publication Number Publication Date
TW201536359A TW201536359A (zh) 2015-10-01
TWI590837B true TWI590837B (zh) 2017-07-11

Family

ID=54067009

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103110985A TWI590837B (zh) 2014-03-25 2014-03-25 一種用於治療心臟病之吸入式醫藥組成物及其備製方法

Country Status (6)

Country Link
US (1) US9375396B2 (zh)
JP (1) JP2015183006A (zh)
KR (1) KR20150111328A (zh)
CN (1) CN104940223A (zh)
DE (1) DE102015104360A1 (zh)
TW (1) TWI590837B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI586383B (zh) * 2014-04-18 2017-06-11 林信湧 一種用於治療關節炎之吸入式醫藥組成物及其備製方法
JP6666701B2 (ja) * 2015-12-01 2020-03-18 日本光電工業株式会社 水素ガス供給装置
CN113599387B (zh) * 2021-09-15 2023-03-28 山东中医药大学附属医院 一种复方制剂及其在制备治疗心绞痛药物中的用途
CN117899106A (zh) * 2022-10-11 2024-04-19 上海氢医医疗科技有限公司 氢气吸入干预早产儿促进发育

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19734279A1 (de) * 1997-08-07 1999-02-11 Messer Griesheim Gmbh Wasserstoffhaltiges Medikament
DK0921807T3 (da) * 1996-08-27 2004-03-15 Messer Griesheim Gmbh Hydrogenholdigt lægemiddel
WO2003018058A1 (fr) * 2001-08-22 2003-03-06 Mitsuhiro Yokota Inhibiteur d'apoptose de cellules myocardiques
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
JP6058888B2 (ja) * 2008-07-24 2017-01-11 ゲノ エルエルシー 患者における心臓の病気の診断及び治療方法
EP2413902B1 (en) * 2009-03-18 2019-07-17 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
IN2014DN10597A (zh) * 2012-06-04 2015-09-11 Miz Co Ltd

Also Published As

Publication number Publication date
JP2015183006A (ja) 2015-10-22
DE102015104360A1 (de) 2015-10-01
US9375396B2 (en) 2016-06-28
TW201536359A (zh) 2015-10-01
KR20150111328A (ko) 2015-10-05
US20150272868A1 (en) 2015-10-01
CN104940223A (zh) 2015-09-30

Similar Documents

Publication Publication Date Title
TWI602585B (zh) 一種用於治療阿茲海默症之吸入式醫藥組成物及其備製方法
TWI601542B (zh) 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
TWI629071B (zh) 保健氣體產生器
TWI590837B (zh) 一種用於治療心臟病之吸入式醫藥組成物及其備製方法
TWI589308B (zh) 一種用於治療帕金森氏症之吸入式醫藥組成物及其備製方法
TWI569816B (zh) 一種用於治療痛風之吸入式醫藥組成物及其備製方法
TWI594772B (zh) 一種用於治療高血壓之吸入式醫藥組成物及其備製方法
TWI586383B (zh) 一種用於治療關節炎之吸入式醫藥組成物及其備製方法
TWI590838B (zh) 一種用於治療糖尿病之吸入式醫藥組成物及其備製方法
TWI586382B (zh) 一種用於治療腎臟病之吸入式醫藥組成物及其備製方法